Want to see XCUR full AI Analyst Report?
XCUR Stock Chart & Stats
$1.26
-$0.01(-0.57%)
At close: 4:00 PM EDT
$1.26
-$0.01(-0.57%)
Day’s Range― - ―
52-Week Range$0.94 - $9.48
Previous Close$1.7
Volume19.01K
Average Volume (3M)36.24K
Market Cap
$7.33M
Enterprise Value$11.54M
Total Cash (Recent Filing)$1.72M
Total Debt (Recent Filing)$0.00
Price to Earnings (P/E)―
Beta1.34
Next Earnings
Nov 12, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-1.31
Shares Outstanding6,545,995
10 Day Avg. Volume49,220
30 Day Avg. Volume36,245
Financial Highlights & Ratios
PEG Ratio0.14
Price to Book (P/B)8.69
Price to Sales (P/S)0.00
P/FCF Ratio-3.99
Enterprise Value/Market Cap1.57
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit-43.88
Enterprise Value/Ebitda-1.35
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Debt ReductionEliminating debt materially reduces interest and refinancing pressure compared with prior years, giving Exicure a cleaner capital structure. This improvement does not solve its funding needs, but it removes leverage as an additional drain on scarce resources while management addresses ongoing losses.
Improved Loss ProfileLower losses than in 2023–2024 indicate some progress in controlling the scale of operating deterioration. If maintained, that improvement could extend the company’s financial runway and reduce the pace of capital depletion, although current results still do not support self-sustaining operations.
Proprietary SNA PlatformA proprietary spherical nucleic acid platform gives Exicure a defined technology base around which it can pursue immuno-oncology and inflammatory-disease programs. Advancing candidates through preclinical and clinical evaluation preserves potential strategic value beyond the company’s current lack of product revenue.
Bears Say
No Commercial RevenueThe absence of commercial revenue means Exicure has not yet demonstrated product-market traction or an internally funded operating model. Continued dependence on research progress, financing, or potential collaborations leaves future cash generation uncertain and makes financial performance highly sensitive to development outcomes.
Persistent Cash BurnOngoing negative operating and free cash flow shows that the business continues consuming capital to fund operations rather than generating resources internally. Unless spending falls materially or new funding is secured, recurring burn can shorten financial runway and constrain investment in its therapeutic programs.
Equity And Listing RiskSeverely reduced stockholders’ equity creates pressure to raise capital or otherwise strengthen the balance sheet, potentially limiting strategic flexibility. Nasdaq’s extension does not restore compliance; failure to meet the deadline could lead to delisting, adding a material structural risk to the company’s financing and operations.
Exicure News
XCUR FAQ
What was Exicure Inc’s price range in the past 12 months?
Exicure Inc lowest stock price was $0.94 and its highest was $9.48 in the past 12 months.
What is Exicure Inc’s market cap?
Exicure Inc’s market cap is $7.33M.
When is Exicure Inc’s upcoming earnings report date?
Exicure Inc’s upcoming earnings report date is Nov 12, 2026 which is in 24 days.
How were Exicure Inc’s earnings last quarter?
Exicure Inc released its earnings results on Aug 07, 2026. The company reported -$0.176 earnings per share for the quarter.
Is Exicure Inc overvalued?
According to Wall Street analysts Exicure Inc’s price is currently Overvalued.
Does Exicure Inc pay dividends?
Exicure Inc does not currently pay dividends.
What is Exicure Inc’s EPS estimate?
Exicure Inc’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Exicure Inc have?
Exicure Inc has 6,545,995 shares outstanding.
What happened to Exicure Inc’s price movement after its last earnings report?
Exicure Inc reported an EPS of -$0.176 in its last earnings report. Following the earnings report the stock price went down -0.37%.
Which hedge fund is a major shareholder of Exicure Inc?
Currently, no hedge funds are holding shares in XCUR
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
Exicure Inc
Exicure, Inc. does not have significant operations. Previously, it focused on developing nucleic acid therapies targeting ribonucleic acid against validated targets. The company has a co-development agreement with Adbiotech Co., Ltd. to explore combination therapies based on Burixafor (GPC-100) across multiple therapeutic areas. Exicure, Inc. was founded in 2011 and is headquartered in Redwood City, California.
Technical Analysis
Ownership Overview
58.38% Insiders
0.92% Mutual Funds
<0.01% Other Institutional Investors
40.26% Public Companies and
Individual Investors